WALTHAM, Mass., July 30, 2015 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced the promotion of Stephen Kennedy to Chief Technology Officer, effective immediately. Mr. Kennedy brings more than 30 years of executive product development, manufacturing, technology assessment and commercialization experience at leading biotechnology companies and esteemed academic institutions, including Genzyme, MIT, and Genencor. He has substantial experience taking early-stage technologies through development, approval and commercial launch using a variety of U.S. and global regulatory pathways, including biologics, drugs and medical devices, and will oversee all manufacturing, research & development, technology assessment, intellectual property and collaboration activities with our advisory board and collaboration partners.
“Steve has been a leading architect of our start-up activities for our NeoCart® Phase 3 trial, including our recent raw material qualification and validation efforts at our facility in Lexington, Massachusetts. His promotion to Chief Technology Officer reflects his substantial contributions since he joined Histogenics,” stated Adam Gridley, President and Chief Executive Officer of Histogenics. “Steve has led many of our recent research and development initiatives, including the launch of our leading Scientific Advisory Board, and spearheaded the initiation and development of our exclusive channel collaboration with Intrexon for next-generation allogeneic products based on the NeoCart® technology platform. Steve will join our recent additions to our executive management team in supporting our Phase 3 clinical trial of NeoCart® and pipeline activities, and we’re pleased to recognize his efforts in this well-deserved promotion.”
Prior to joining Histogenics in 2013 as Senior Vice President of Technical Operations, Mr. Kennedy served as the Executive Vice President, Research and Development, at Mascoma Corporation, a biofuel company from 2011 to 2013. Prior to that, Mr. Kennedy spent 18 years at Genzyme Corporation, where he held several senior leadership roles in Technical Operations, as the company developed from small start-up to a major player in the biopharmaceutical industry. As Genzyme’s Senior Vice President of Biologics Technical Operations, he developed cGMP biologics manufacturing operations at facilities in Belgium and France, oversaw Genzyme’s gene therapy operation in San Diego, and formed the global Biologics Operations organization. Before this, Mr. Kennedy developed the manufacturing process optimization organization that supported Genzyme’s full range of products, including all biologics, Carticel® and hyaluronic acid products, such as Seprafilm®. Early in his career at Genzyme, Mr. Kennedy focused on implementation and optimization of cell culture manufacturing technologies used in the production of flagship products at Genzyme, including Ceredase® and Cerezyme®. He has also served as Executive Director of the Novartis/MIT Center for Continuous Manufacturing at the Massachusetts Institute of Technology. Mr. Kennedy has a B.S. from the University of Michigan, an M.S. from the University of Rochester and an M.B.A. from Boston University.
About Histogenics Corporation
Histogenics is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal segment of the marketplace. Histogenics’ regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions that can be utilized individually or in concert to treat musculoskeletal-related conditions. Histogenics’ first investigational product candidate, NeoCart®, leverages its platform to provide an innovative treatment in the orthopedic space, specifically cartilage damage in the knee.
